On November 1, 2022 AIGEN Sciences reported the company signed a joint research and development agreement with Noveltinobility to develop an artificial intelligence (AI)-based antibody-drug conjugate (ADC) (Press release, AIGEN Sciences, NOV 1, 2022, View Source [SID1234643562]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In this joint development, Eisen Science is responsible for designing and synthesizing drugs (payloads) with high selectivity and apoptosis function for cancer cells by applying its own artificial intelligence platform. Noveltinobility is responsible for new ADC design and evaluation of drug efficacy and toxicity using its expertise in antibody new drug development and the payload developed by Eisen Science. The goal of both companies is to develop ADC drugs that increase treatment effectiveness while minimizing side effects.
Eisen Science has a platform technology that can screen and design drugs with new structures that induce transcriptome changes similar to knock down expression of disease targets using transcriptome data-based artificial intelligence technology. The explanation is that through this, off-target side effects of the drug can be minimized.
Novelinobility is an antibody-based innovative new drug development company that has PREXISE-D, a fully human antibody discovery platform using humanized mice (Hu-mice). Novelty is developing pipelines such as single antibodies, ADCs, and double antibodies using antibodies discovered directly using this platform. In addition, Novelty is advancing the ADC linker platform technology PREXISE-L and promoting the development of next-generation ADC through cooperation with biotech companies specialized in developing new drugs for small molecule compounds.
Park Sang-gyu, CEO of Novelinobility, said, "Through cooperation with Igenscience, we have accelerated the development of the next-generation ADC pursued by the company." He added, "If we combine our know-how in developing new antibody drugs with Igenscience’s artificial intelligence platform, we can achieve diverse functionality and excellent drug efficacy." -We expect to be able to develop an ADC with toxicity balance," he said.
Jae-Woo Kang, CEO of Eisen Science, said, "We want to apply artificial intelligence to the development of ADC anticancer drugs through joint development with Nobel Innovation." He added, "The development of a new payload using Eisen Science’s artificial intelligence platform based on transcriptome data is expected to expand the ADC development market. "We expect it to contribute to the expansion," he said.